Structural GenomiX Acquires Troxatyl® from Shire
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 51 (Table of Contents)
Published: 4 Sep-2004
DOI: 10.3833/pdr.v2004.i51.778 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Structural GenomiX entered into license agreement with Shire BioChem to acquire worldwide rights for anticancer drug, Troxatyl® (troxocitabine) for treating acute myeloid leukemia and solid tumors...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS